EUCTR2006-001914-34-DE进行中（未招募）不适用
Treatment of neovascular age related macular degeneration with intravitreal Bevacizumab (Avastin)
Bert Mueller, Dep. Ophthalmology0 个研究点开始时间: 2006年5月8日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients older than 50 years, neovascular age related macular degeneration, loss of visual acuity within 3 months prior to inclusion
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •allergy to bevacizumab, contraindication to bevacizumab (unstable Angina pectoris, recent myocardial infarction and stroke), other ocular disease
研究者
相似试验
已完成
不适用
Treating neovascular age-related macular degeneration with aflibercepteovascular age-related macular degenerationEye DiseasesISRCTN58955026York Hospital40
进行中（未招募）
1 期
The MATE studyEUCTR2015-002302-36-GBYork Teaching Hospital40
进行中（未招募）
1 期
Managing neovascular age-related macular degeneration over 2 years using of different schedules of 2 mg aflibercept injected in the eye (ARIES)eovascular age-related macular degeneration (nAMD)EUCTR2014-003132-39-FRBayer HealthCare AG268
进行中（未招募）
1 期
Managing neovascular age-related macular degeneration over 2 years using of different schedules of 2 mg aflibercept injected in the eye (ARIES)eovascular age-related macular degeneration (nAMD)EUCTR2014-003132-39-GBBayer AG287
进行中（未招募）
1 期
Managing neovascular age-related macular degeneration over 2 years using of different schedules of 2 mg aflibercept injected in the eye (ARIES)eovascular age-related macular degeneration (nAMD)EUCTR2014-003132-39-ESBayer HealthCare AG268